CNS Cohen & Steers Forecast, Technical & Fundamental Analysis

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 41 of 60 cases where CNS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CNS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.

The Aroon Indicator for CNS entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CNS's RSI Indicator exited the oversold zone, 13 of 24 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 54%.

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on CNS as a result. In 48 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.

The Moving Average Convergence Divergence (MACD) for CNS just turned positive on October 20, 2026. Looking at past instances where CNS's MACD turned positive, the stock continued to rise in 24 of 45 cases over the following month. The odds of a continued upward trend are 53%.

CNS moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CNS crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.

Following a +4.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where CNS advanced for three days, in 182 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 33 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. CNS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.387) is normal, around the industry mean (2.412). P/E Ratio (22.385) is within average values for comparable stocks, (-2.386). Projected Growth (PEG Ratio) (1.671) is also within normal values, averaging (1.319). Dividend Yield (0.037) settles around the average of (0.270) among similar stocks. P/S Ratio (6.139) is also within normal values, averaging (15.694).

The Tickeron Profit vs. Risk Rating rating for this company is 94 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CNS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.